Introduction
With increased understanding of the molecular events occurring during the development of acute myeloid leukemia (AML), the number of potential targets for therapy has also grown. These targets can be placed into three broad categories. First, there are the immediate consequences of the mutational events leading to AML, such as mutated FLT3 or RAS. A second broad category of targets are those adaptive nonmutational changes a leukemic cell must make in order to survive given the initial mutational event, for example, the increased expression of BCL2 seen in most AML samples. A third category of targets includes the cell surface antigens that distinguish AML cells from the normal hematopoietic stem cell.
Mutational events as targets
Mutations in tyrosine kinase receptors occur in a substantial proportion of cases of AML. The most common abnormalities are in the FLT3 receptor tyrosine kinase, with internal tandem duplications found in 15-30% of cases of AML and point mutations seen in another 5-10%. 1, 2 Point mutations in C-FMS are found in 10-20% of cases of AML 3 while various mutations in C-KIT are seen in 5-10% of cases. 4 Given the frequency of FLT3 mutations in AML, this abnormality has generated a great deal of interest as a potential therapeutic target. Recent work suggests that both the internal tandem duplications and the point mutations of FLT3 seen in AML are activating. Such activation induces factor-independent proliferation of human hematopoietic cell lines, and an activated FLT3 receptor in transgenic mice produces a myeloproliferative syndrome. 5 The fact that a mutant FLT3 in mice does not result in full-blown leukemia suggests that other genetic events, such as mutations in genes affecting differentiation, are also required for the development of overt AML. 6 While one or another form of FLT3 mutation is found in 20-40% of AML cases, it appears to be more commonly seen in cases with t(15;17) and t(6;9), and only rarely seen with À7, À5, t(8;21), inversion (16) or with mutated RAS. 7 Patients with FLT3 mutations generally present with a higher white count and, in most studies, have had a poorer overall outcome. [7] [8] [9] [10] The specific FLT3 mutation found at diagnosis is usually also present at relapse. The central role of FLT3 in the development of AML has led to a search for small-molecule inhibitors of FLT3 and at least four are currently in early clinical trials with results likely forthcoming soon. [11] [12] [13] [14] These agents include CEP-701, an indolocarbazole derivative; PKC-412, a staurosporine derivative; SU11248, an indolinone-based inhibitor; and CT53518, a compound in the piperazinyl quinazoline class. All four are thought to block ATP binding to FLT3. These small molecules induce apoptosis of human FLT3 positive AML cell lines and prolong survival in nude mouse models of FLT3 positive AML.
RAS molecules are a group of signaling proteins 'downstream' of many tyrosine kinase receptors, which, following receipt of a signal from a receptor tyrosine kinase, in turn activate a broad range of other proteins involved in cell proliferation and survival. Among the more prominent proteins activated by RAS are the MAP/ERK kinase involved in cell proliferation, Rac and Rho, which influence cytoskeletal organization and PI-3 kinase, which may protect against apoptosis. In 15-20% of cases of AML, mutations in members of the RAS family are found, most commonly in N-RAS and less frequently in K-RAS and H-RAS. 15 The RAS proteins are synthesized as cytosolic precursors and require the addition of a farnesyl group to attach to the cell membrane and transmit signals. Thus, there exists a strong rationale to test agents that block the farnesylation of RAS in patients with AML, particularly if their leukemias carry a mutation in RAS. The farnesyltransferase inhibitor R11597 is one such molecule, which in a dose escalation study involving 35 leukemic patients including 26 with AML, showed definite antileukemic activity. 16 In this study, CNS toxicity was found to be dose limiting at 1200 mg b.i.d. Two complete responses and eight partial responses were seen in these 35 patients. Whether the agent actually functions via inhibition of RAS is uncertain, since there was no correlation in the study between inhibition of farnesyltransferase and clinical response. A number of other farnesyltransferase inhibitors are in clinical trials, including BMS 214662 and SCH 66336.
Histones are proteins closely associated with chromatin. In the unacetylated state, the protein tails of histones anchor the associated chromatin and repress local transcription in the region of the nucleosome. If histones are acetylated, the protein tails become unanchored, allowing the structure to relax, unwind, and for genes near these complexes to become transcriptionally active. In certain AMLs, like those associated with t(15;17) and t(8;21), the resulting abnormal fusion product of the translocation binds to the normal promoter target genes and also binds a transcriptional repressor complex that includes a histone deacetylase, with the result that the chromatin in that region becomes deacetylated and transcription of the target genes is repressed. 17 These repressed genes may be important for cellular differentiation and eventual apoptosis, so that their lack of expression may be key to the leukemic process. Thus, molecules that inhibit histone deacetylases are being studied as antileukemic agents, 18 including phenylbutyrate, trichostatin, trapoxin, depsipeptide, and MS-275.
Adaptive responses as targets
The mutational event, or events, that give rise to AML may also require the cell to make other adaptive changes in order to survive. Since these changes are not required of normal cells, inhibiting them may result in specific damage or death to AML cells. Similarly, once stressed or damaged, AML cells may become more dependent than normal cells on the function of certain pathways and, thus, blocking these pathways may specifically sensitize malignant cells to conventional therapy. One example of an adaptive change is the antiapoptotic gene Bcl-2, which is overexpressed in almost all AML samples compared to normal marrow. Bcl-2 expression is further increased following exposure to Ara-C or other antileukemic agents and a high expression of Bcl-2 proteins has been associated with poor response rates in AML. 19, 20 In vitro studies have demonstrated that antisense Bcl-2 is capable of sensitizing AML cells to the cytotoxic effects of Ara-C, thus providing the basis for ongoing clinical studies of Bcl-2 antisense combined with chemotherapy in patients with recurrent AML. 21 Like Bcl-2, peripheral benzodiazepine receptors reside in mitochondrial pores, are overexpressed in AML, and protect cells from apoptotic cell death. In a manner analogous to Bcl-2 antisense, PK11195, a peripheral benzodiazepine receptor ligand, sensitizes AML cells to cytarabine and daunomycin. 22 Another adaptive response that occurs upon cell injury is enhanced cholesterol synthesis. Following exposure to radiation or chemotherapy, surviving cells greatly increase cholesterol synthesis acquiring a state of cytoresistance. If re-exposed to identical doses of damaging agents, such cells then exhibit relative resistance to the treatments. If cholesterol synthesis and uptake are blocked, the acquired cytoresistance is diminished and the cells will remain sensitive to the damaging agents. Even in the absence of exposure to cell damaging agents, AML cells have increased cholesterol turnover. Dimitroulakos et al 23 and Wong et al 24 showed that lovastatin, which blocks de novo cholesterol synthesis, killed six of seven AML cell lines and 13 of 22 primary AML cell cultures. We have since shown that AML cells increase cholesterol synthesis much more than normal hematopoietic cells do upon exposure to daunomycin, cytarabine, or radiation, and that blocking cholesterol synthesis using mevastatin or zaragozic acid specifically sensitizes most AML cell lines and patient AML samples, but has no discernible effect on normal hematopoietic progenitors. 25 
Cell surface antigens as targets
Cell surface antigens are being explored as targets for antibody and cellular-based immunotherapies. CD33 is a glycoprotein found on blasts in more than 90% of cases of AML. It is also expressed on almost all normal early myeloid and erythroid progenitors, but is not expressed on the hematopoietic stem cell or by nonhematopoietic tissue. A humanized anti-CD33 antibody, HUM195, has been studied as a single agent and led to transient drops in peripheral blasts but only a rare complete response. 26 This agent has more recently been studied as treatment for patients with minimal residual disease or in combination with standard chemotherapy. Given the capability of antibodies to CD33 to target specifically myeloid leukemia cells while avoiding the normal hematopoietic stem cell and nonhematopoietic tissues, working with investigators from Wyeth-Ayerst, we developed the drug immunoconjugate gemtuzumab ozogamicin, which joins a humanized anti-CD33 IgG4 antibody with the potent antitumor antibiotic calicheamicin. In phase II studies in patients with AML in first relapse, gemtuzumab had a 30% complete response rate. 27 The major toxicities seen were the expected myelosuppression in essentially all patients, liver function abnormalities in 17% (including fatal veno-occlusive disease in one), infection in 16%, and mucositis in 4%. Based on the toxicity profile, which appears somewhat more favorable than intensive combination chemotherapy, gemtuzumab was approved by the FDA for treatment of recurrent AML last year. Preliminary results of the addition of gemtuzumab on day 4 of a standard daunomycin for 3 days and cytarabine for 7 days regimen appear very encouraging, and are being further evaluated in a phase III Southwest Oncology Group trial.
CD45 and CD66 are antigens found on virtually all hematopoietic cells. Antibody-radionuclide conjugates to these targets are being studied in the context of hematopoietic cell transplantation. These studies are based on previous trials demonstrating that escalation in the dose of preparative regimens for transplantation is associated with decreased relapse rates post-transplant, but with higher rates of serious toxicities. Thus, by targeting locally acting radionuclides to normal and malignant marrow it may be possible to diminish post-transplant relapse rates without increased toxicities. Phase II trials using a [
131 I] anti-CD45 antibody combined with busulfan and cyclophosphamide have yielded encouraging results with 70% of 40 patients with AML in first remission, so far treated, predicted to remain disease free at 5 years. 28 Similar encouraging results have been reported using [ 88 Re] anti-CD66. 29 The reduced relapse rates associated with the development of graft-vs-host disease following allogenic transplantation have raised interest in the development of cellular-based therapies for AML. These interests have been further strengthened by the ability of donor lymphocyte infusions to induce complete remissions in some patients who have relapsed post-transplant. Two general groups of targets are being considered in studies attempting to segregate the potentially potent graftvs-tumor effect from graft-vs-host disease. One set of targets includes polymorphic minor histocompatibility antigens with expression largely limited to hematopoietic tissues. Such antigens should be capable of serving as targets post-transplant for donor-derived T cells that would destroy all normal and malignant host hematopoietic tissue but not contribute to graft-vs-host disease. A number of polymorphic minor histocompatibility antigens with expression restricted to hematopoietic tissue have been identified by the groups in Seattle and Leiden. Studies using T cells targeted to these antigens are under way. 30, 31 Attempts are also under way to identify nonallogeneic targets for cellular therapy. Such targets could be mutational fusion proteins, such as BCR-abl or Dek-can, or overexpressed selfantigens, such as PR3 and WT1. Translocations such as BCR-abl produce fusion product proteins that are not expressed by normal cells, which could then serve as tumor-specific peptide targets. Thus, attempts are being made to elicit antitumor responses by immunizing patients with vaccines based on these mutant peptides. 32 Several nonmutated proteins are highly overexpressed in AML cells, including PR3 and WT1. 33, 34 T cells with specificity to these antigens can be generated that selectively lyse leukemic blasts but do not damage normal CD34 positive hematopoietic cells. Thus, these proteins are now being studied as targets for adoptive T-cell or vaccine strategies.
